3883 related articles for article (PubMed ID: 6239687)
1. Isolated soluble fractions from the murine B16 melanoma induce primary in vitro syngeneic antitumor responses.
Klein BY; Frenkel S; Naor D
Cancer Immunol Immunother; 1984; 18(3):195-202. PubMed ID: 6239687
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of subcellular fractions and molecular species of MuLV-induced tumors. III. Stimulation of syngeneic antitumor responses by subcellular fractions and molecular species of Moloney virus-induced tumors in CBA and A mice.
Ahituv A; Naor D; Sharon R; Tarcic N; Klein BY
Cancer Immunol Immunother; 1982; 14(1):16-26. PubMed ID: 6186365
[TBL] [Abstract][Full Text] [Related]
3. The isolation of immunogenic molecular entities from immunogenic and nonimmunogenic tumor homogenates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Sharon R; Naor D
Cancer Immunol Immunother; 1984; 18(3):203-8. PubMed ID: 6239688
[TBL] [Abstract][Full Text] [Related]
4. Immune responses to weakly immunogenic virally induced tumors. I. Overcoming low responsiveness by priming mice with a syngeneic in vitro tumor line or allogeneic cross-reactive tumor.
Galili N; Devens B; Naor D; Becker S; Klein E
Eur J Immunol; 1978 Jan; 8(1):17-22. PubMed ID: 639838
[TBL] [Abstract][Full Text] [Related]
5. Immune responses to weakly immunogenic virally induced tumors. III. Genetically unrestricted cytolysis of allogeneic tumor target cells.
Devens B; Naor D
J Immunol; 1979 Apr; 122(4):1397-401. PubMed ID: 312839
[TBL] [Abstract][Full Text] [Related]
6. Methods for amplifying the induction and expression of cytotoxic response in vitro to syngeneic and autologous freshly-isolated solid tumors of mice.
Kedar E; Chriqui-Zeira E; Mitelman S
Cancer Immunol Immunother; 1984; 18(2):126-34. PubMed ID: 6239683
[TBL] [Abstract][Full Text] [Related]
7. In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells.
Ashley MP; Kotlarski I
Cell Immunol; 1986 Aug; 101(1):156-67. PubMed ID: 3742604
[TBL] [Abstract][Full Text] [Related]
8. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
9. Immune response to weakly immunogenic virally induced tumors. IX. Mice injected with the in vitro variant of YAC tumor (YAC-1) resist lethal doses of the tumorigenic YAC cells.
Devens B; Deutsch O; Avraham Y; Naor D
Immunobiology; 1981; 159(4-5):432-43. PubMed ID: 7287048
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of therapeutic antitumor immunity by B16F10 melanoma cells transfected by interferon-gamma and allogeneic MHC class I cDNAs.
Lim YS; Kang BY; Kim EJ; Kim SH; Hwang SY; Kim TS
Mol Cells; 1998 Oct; 8(5):629-36. PubMed ID: 9856353
[TBL] [Abstract][Full Text] [Related]
11. Recombinant adenovirus-transduced dendritic cell immunization in a murine model of central nervous system tumor.
Broder H; Anderson A; Odesa SK; Kremen TJ; Liau LM
Neurosurg Focus; 2000 Dec; 9(6):e6. PubMed ID: 16817689
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
Fidler IJ; Bucana C
Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
[TBL] [Abstract][Full Text] [Related]
13. Immune responses to weakly immunogenic virally induced tumors. II. Suppressive effects of the in vivo carried tumor YAC.
Devens B; Galili N; Deutsch O; Naor D; Klein E
Eur J Immunol; 1978 Aug; 8(8):573-8. PubMed ID: 699954
[TBL] [Abstract][Full Text] [Related]
14. Syngeneic monoclonal antibodies to B16 melanoma viral antigens.
Rappaport I; Alterman AL; Braverman S; Stackpole CW
Cancer Res; 1987 Oct; 47(20):5391-6. PubMed ID: 3652042
[TBL] [Abstract][Full Text] [Related]
15. Impaired H-2 expression in B16 melanoma variants.
Nanni P; Colombo MP; De Giovanni C; Lollini PL; Nicoletti G; Parmiani G; Prodi G
J Immunogenet; 1983 Oct; 10(5):361-70. PubMed ID: 6644070
[TBL] [Abstract][Full Text] [Related]
16. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
17. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
Kim TS; Xu WS; Sun T; Cohen EP
Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
[TBL] [Abstract][Full Text] [Related]
18. Characterization of effector cells against B16 melanoma in mice inoculated with allogeneic spleen cells.
Nishi Y; Hosokawa T; Aoike A; Han D; Takehara H; Kawai K; Kamahora T
Microbiol Immunol; 1994; 38(3):217-23. PubMed ID: 7915815
[TBL] [Abstract][Full Text] [Related]
19. [Cytotoxic immunity indices of melanoma B16 growth in mice].
Korosteleva TA; Veresova OV
Vopr Onkol; 1980; 26(1):67-70. PubMed ID: 7355591
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic T lymphocytes reactive against a syngeneic murine tumor and their specific suppressor T cells are both elicited by in vitro allosensitization.
Leshem B; Kedar E
J Exp Med; 1990 Apr; 171(4):1057-71. PubMed ID: 2139097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
